Aurobindo Pharma Limited’s subsidiary, Acrotech Biopharma, has achieved a significant milestone by securing approval from the U.S. Food and Drug Administration (FDA) for its innovative product, ADQUEY. This ointment, containing difamilast at a concentration of 1%, is designed for the topical treatment of mild-to-moderate atopic dermatitis, marking a promising advancement in dermatological care.
Collaboration with Otsuka Pharmaceutical
Acrotech Biopharma, renowned for its commitment to developing unique therapeutics, collaborated with Otsuka Pharmaceutical Co., Ltd. to bring ADQUEY to market. The FDA’s approval of the New Drug Application (NDA) is a pivotal moment not only for Acrotech but also for the millions affected by atopic dermatitis in the United States, including both adults and children aged two and older.
A New Era in Treatment Options
ADQUEY introduces a novel approach to managing atopic dermatitis, standing out as a non-steroidal treatment option. It acts as a phosphodiesterase 4 (PDE4) inhibitor, a mechanism that offers patients an alternative to traditional steroid-based therapies. This advancement is particularly significant given the growing demand for long-term solutions that effectively manage the symptoms of eczema, such as inflammation and itching.
Clinical Trials Validate Efficacy
The FDA’s decision was underpinned by robust clinical evidence. Pivotal Phase III controlled trials demonstrated that patients treated with ADQUEY experienced significantly better outcomes in terms of Investigator’s Global Assessment (IGA) success compared to those receiving a placebo after four weeks of treatment. The consistency of ADQUEY’s safety profile across studies further bolstered its approval, with nasopharyngitis being the most frequently reported adverse reaction.
Understanding Atopic Dermatitis
Atopic dermatitis, commonly known as eczema, is a prevalent and chronic skin condition that results in itchy, dry, and inflamed skin. While it primarily manifests in childhood, it can occur at any age, affecting daily life and overall well-being. The introduction of ADQUEY provides a much-needed solution for those seeking effective management of this condition.
Formulation and Dosage
ADQUEY is formulated as a topical ointment for easy application, designed for use twice daily. Its mechanism involves targeting all phosphodiesterase-4 subtypes, which enhances its ability to mitigate the symptoms associated with eczema. The product’s development journey began with Otsuka Pharmaceutical, which discovered and developed difamilast before licensing it to Acrotech in 2021.
Safety and Tolerability
The safety profile of ADQUEY has been favorable, with the most common adverse reaction being nasopharyngitis reported in 6% of patients. Other less frequent reactions include application site folliculitis and contact dermatitis. This favorable safety record is crucial in establishing trust among healthcare providers and patients alike.
A Commitment to Dermatology
Ashish Anvekar, President of Acrotech Biopharma Inc., expressed the company’s dedication to enhancing dermatological care through the approval of ADQUEY. He emphasized the need for effective and long-term non-steroidal treatment options, aligning the company’s mission with the expectations of patients and clinicians.
Looking Ahead
With FDA approval secured, Acrotech Biopharma is poised to launch ADQUEY in the U.S. market, bridging an important gap in the treatment landscape for atopic dermatitis. The company’s commitment to delivering innovative therapeutic solutions is expected to resonate well with healthcare providers and patients alike.
Key Takeaways:
- Acrotech Biopharma received FDA approval for ADQUEY, a topical treatment for atopic dermatitis.
-
This non-steroidal ointment offers an alternative to traditional steroid-based therapies.
-
Clinical trials support the efficacy and safety of ADQUEY, with favorable outcomes for patients.
-
The collaboration with Otsuka Pharmaceutical enhances the credibility and reach of this innovative treatment.
-
ADQUEY is designed for easy application, making it user-friendly for patients of all ages.
In conclusion, the approval of ADQUEY marks a transformative step in the management of atopic dermatitis. With its innovative formulation and supportive clinical data, Acrotech Biopharma is set to make a meaningful impact in the lives of those affected by this challenging condition.
Read more → medicaldialogues.in